Skip to main content

Table 3 Clinical events during follow-up

From: Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials

Events High-dose of RSV n (%) Control n (%) P
Stable    
 Death 2(0.6 %) 3(1.0 %) 0.42
 Spontaneous MI 5(1.4 %) 7(2.4 %) 0.34
 TVR 5(1.4 %) 12(4.2 %) 0.05
 MACE 12(3.3 %) 22(7.7 %) 0.02
ACS    
 Death 7(0.7 %) 15(1.6 %) 0.09
 Spontaneous MI 7(0.7 %) 20(2.1 %) 0.02
 TVR 19(2.0 %) 37(3.9 %) 0.01
 MACE 33(3.5 %) 72(7.6 %) <0.0001
Overall    
 Death 9(0.7 %) 18(1.5 %) 0.06
 Spontaneous MI 12(0.9 %) 27(2.2 %) 0.01
 TVR 24(1.8 %) 49(4.0 %) 0.002
 MACE 45(3.5 %) 94(7.6 %) <0.00001
Statin naïve    
 Death 7(0.7 %) 15(1.6 %) 0.09
 Spontaneous MI 8(0.8 %) 21(2.2 %) 0.02
 TVR 20(2.1 %) 40(4.2 %) 0.008
 MACE 35(3.7 %) 76(8.0 %) <0.0001
Prior statin treatment    
 Death 1(0.4 %) 2(1.2 %) 0.3
 Spontaneous MI 2(0.8 %) 5(3.0 %) 0.13
 TVR 3(1.2 %) 7(4.2 %) 0.09
 MACE 6(2.4 %) 14(8.4 %) 0.01
Overall    
 Death 8(0.7 %) 17(1.5 %) 0.05
 Spontaneous MI 10(0.8 %) 26(2.3 %) 0.005
 TVR 23(1.9 %) 47(4.2 %) 0.002
 MACE 41(3.4 %) 90(8.0 %) <0.00001
  1. ACS acute coronary syndrome, Spontaneous MI spontaneous myocardial infarction, TVR target vessel revascularization, MACE major adverse cardiovascular events